# Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

> **NCT00743795** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 252 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** placebo
- **DRUG:** GS-9190
- **DRUG:** Peginterferon Alfa 2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00743795
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-07
- **Final completion:** 2013-09
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2013-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743795, "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00743795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*